April 4, 2019
Cefazolin shortages caused by the suspension of generic supplies by Nichi-Iko Pharmaceutical, which holds the lion’s share in that compound’s market, might signal the risks of supply shortfalls following the withdrawal of off-patent original drugs under the so-called G1/G2 scheme...read more